top of page
gradientForSurfBreak.png

Item List

Businesswire
Epitel Expands AI Portfolio With A Fourth FDA 510(k) Clearance for REMI

Epitel, a leader in AI for patient-focused brain health technologies, announced today it received U.S. Food and Drug Administration (FDA) 510(k) clearance for REMI Vigilenz™ AI For Bedside Notifications. REMI Vigilenz AI For Bedside Notifications conducts an automated analysis of EEG data collected by the REMI™ wireless wearable EEG System in near real-time. Notifications occur when the algorithm recognizes seizure characteristics within a section of EEG.

Recent Posts

Portfolio Company

Carlsmed.png

Citizen Health Announces $14.5 Million Seed Funding and Partnerships to Transfor ...

Chan Zuckerberg Initiative

Portfolio Company

Carlsmed.png

xCures Unveils Next-Generation AI-Powered Data Platform ...

Engineering

Portfolio Company

Carlsmed.png

Gradient Health announces acquisition of DataAppraisal to accelerate medical AI ...

HealthCare Business

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page